论文部分内容阅读
作者采用非损伤性检查方法,研究了苯甲醚溶纤酶激活因子链激酶复合物(APSAC)治疗急性心肌梗塞(AMI)的再灌注率,左心功能,副作用及预后。选择连续住院的46例(男40、女6)AMI患者符合下列条件:年龄<70岁;发病3小时内,胸痛30分钟以上;ECG出现两个以上肢体导联S-T抬高≥0.1mv,和/或两个以上心前导联S-T抬高≥0.2mv;含服消心痛和/或心痛定后,上述情况无改善;没有溶栓治疗禁忌症及心源性休克。予患者静注APSAC30单位,5分钟注完,4小时后静滴肝素,3～5天内改用Warfarin持续三个月以上.
The authors studied the reperfusion rate, left ventricular function, side effects and prognosis of acute myocardial infarction (AMI) treated with anisodithinase-AC streptokinase complex (APSAC) using a non-invasive method. 46 consecutive AMI patients (male 40, female 6) were eligible for the following conditions: age <70 years; chest pain for more than 30 minutes within 3 hours of onset; ECG with ST elevation ≥0.1 mv for ECG with two or more limbs; and / Or more than two lead ECG ST elevation ≥0.2mv; containing heartburn and / or heartburn set, the above conditions no improvement; no thrombolytic therapy contraindications and cardiogenic shock. To patients with intravenous APSAC30 units, 5 minutes Note End, 4 hours after the infusion of heparin, 3 to 5 days to switch to Warfarin for more than three months.